These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 27262235

  • 21. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N, Möllmann K, Milde-Langosch K, Müller V, Schumacher U, Brandt B, Pantel K, Jücker M.
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M, Gründker C, Fister S, Kubin J, Wilkens L, Mueller MD, Hemmerlein B, Emons G, Günthert AR.
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [Abstract] [Full Text] [Related]

  • 26. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X, Wang ZY.
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [Abstract] [Full Text] [Related]

  • 27. [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].
    Zhen LL, Zhu X, Zheng W, Wang XY, Wu ZY.
    Ai Zheng; 2006 Jul; 25(7):839-43. PubMed ID: 16831274
    [Abstract] [Full Text] [Related]

  • 28. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.
    Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI.
    Endocrinology; 2005 Nov; 146(11):4609-18. PubMed ID: 16037379
    [Abstract] [Full Text] [Related]

  • 29. Regulation of AKT phosphorylation at Ser473 and Thr308 by endoplasmic reticulum stress modulates substrate specificity in a severity dependent manner.
    Yung HW, Charnock-Jones DS, Burton GJ.
    PLoS One; 2011 Mar 21; 6(3):e17894. PubMed ID: 21445305
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells.
    Kim R, Tanabe K, Emi M, Uchida Y, Toge T.
    Cancer; 2005 May 15; 103(10):2199-207. PubMed ID: 15830342
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW, Lin YC.
    Anticancer Res; 2006 May 15; 26(3A):1773-84. PubMed ID: 16827106
    [Abstract] [Full Text] [Related]

  • 35. BI2536--A PLK inhibitor augments paclitaxel efficacy in suppressing tamoxifen induced senescence and resistance in breast cancer cells.
    Prashanth Kumar BN, Rajput S, Bharti R, Parida S, Mandal M.
    Biomed Pharmacother; 2015 Aug 15; 74():124-32. PubMed ID: 26349973
    [Abstract] [Full Text] [Related]

  • 36. The COOH-Terminal Proline-Rich Region of GRP78 Is a Key Regulator of Its Cell Surface Expression and Viability of Tamoxifen-Resistant Breast Cancer Cells.
    Tseng CC, Zhang P, Lee AS.
    Neoplasia; 2019 Aug 15; 21(8):837-848. PubMed ID: 31306849
    [Abstract] [Full Text] [Related]

  • 37. Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.
    Citi V, Del Re M, Martelli A, Calderone V, Breschi MC, Danesi R.
    Cancer Chemother Pharmacol; 2018 Apr 15; 81(4):745-754. PubMed ID: 29476223
    [Abstract] [Full Text] [Related]

  • 38. Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.
    Kurebayashi J, Nukatsuka M, Sonoo H, Uchida J, Kiniwa M.
    Cancer Chemother Pharmacol; 2010 Jan 15; 65(2):219-25. PubMed ID: 19455332
    [Abstract] [Full Text] [Related]

  • 39. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM, Sorokin DV, Tatarskiy VV, Prokhorov NS, Semina SE, Berstein LM, Krasil'nikov MA.
    IUBMB Life; 2016 Apr 15; 68(4):281-92. PubMed ID: 26892736
    [Abstract] [Full Text] [Related]

  • 40. Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer.
    Chen J, Gomes AR, Monteiro LJ, Wong SY, Wu LH, Ng TT, Karadedou CT, Millour J, Ip YC, Cheung YN, Sunters A, Chan KY, Lam EW, Khoo US.
    PLoS One; 2010 Aug 20; 5(8):e12293. PubMed ID: 20808831
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.